Lancet Digital Health最新文献

{"title":"Diagnostic accuracy of a machine learning algorithm using point-of-care high-sensitivity cardiac troponin I for rapid rule-out of myocardial infarction: a retrospective study","authors":"Betül Toprak MD , Hugo Solleder PhD , Eleonora Di Carluccio MSc , Jaimi H Greenslade PhD , Prof William A Parsonage MD , Karen Schulz DC , Prof Louise Cullen MD , Prof Fred S Apple PhD , Prof Andreas Ziegler PhD , Prof Stefan Blankenberg MD","doi":"10.1016/S2589-7500(24)00191-2","DOIUrl":"10.1016/S2589-7500(24)00191-2","url":null,"abstract":"<div><h3>Background</h3><div>Point-of-care (POC) high-sensitivity cardiac troponin (hs-cTn) assays have been shown to provide similar analytical precision despite substantially shorter turnaround times compared with laboratory-based hs-cTn assays. We applied the previously developed machine learning based personalised Artificial Intelligence in Suspected Myocardial Infarction Study (ARTEMIS) algorithm, which can predict the individual probability of myocardial infarction, with a single POC hs-cTn measurement, and compared its diagnostic performance with standard-of-care pathways for rapid rule-out of myocardial infarction.</div></div><div><h3>Methods</h3><div>We retrospectively analysed pooled data from consecutive patients of two prospective observational cohorts in geographically distinct regions (the Safe Emergency Department Discharge Rate cohort from the USA and the Suspected Acute Myocardial Infarction in Emergency cohort from Australia) who presented to the emergency department with suspected myocardial infarction. Patients with ST-segment elevation myocardial infarction were excluded. Safety and efficacy of direct rule-out of myocardial infarction by the ARTEMIS algorithm (at a pre-specified probability threshold of <0·5%) were compared with the European Society of Cardiology (ESC)-recommended and the American College of Cardiology (ACC)-recommended 0 h pathways using a single POC high-sensitivity cardiac troponin I (hs-cTnI) measurement (Siemens Atellica VTLi as investigational assay). The primary diagnostic outcome was an adjudicated index diagnosis of type 1 or type 2 myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction. The safety outcome was a composite of incident myocardial infarction and cardiovascular death (follow-up events) at 30 days. Additional analyses were performed for type I myocardial infarction only (secondary diagnostic outcome), and for each cohort separately. Subgroup analyses were performed for age (<65 years <em>vs</em> ≥65 years), sex, symptom onset (≤3 h <em>vs</em> >3 h), estimated glomerular filtration rate (<60 mL/min per 1·73 m<sup>2</sup> <em>vs</em> ≥60 mL/min per 1·73 m<sup>2</sup>), and absence or presence of arterial hypertension, diabetes, a history of coronary artery disease, myocardial infarction, or heart failure, smoking, and ischaemic electrocardiogram signs.</div></div><div><h3>Findings</h3><div>Among 2560 patients (1075 [42%] women, median age 58 years [IQR 48·0–69·0]), prevalence of myocardial infarction was 6·5% (166/2560). The ARTEMIS-POC algorithm classified 899 patients (35·1%) as suitable for rapid rule-out with a negative predictive value of 99·96% (95% CI 99·64–99·96) and a sensitivity of 99·68% (97·21–99·70). For type I myocardial infarction only, negative predictive value and sensitivity were both 100%. Proportions of missed index myocardial infarction (0·05% [0·04–0·42]) and follow-up events at 30 days (0·07% [95% CI 0·06–0·59]) were l","PeriodicalId":48534,"journal":{"name":"Lancet Digital Health","volume":"6 10","pages":"Pages e729-e738"},"PeriodicalIF":23.8,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The potential for large language models to transform cardiovascular medicine","authors":"Giorgio Quer PhD ,&nbsp;Prof Eric J Topol MD","doi":"10.1016/S2589-7500(24)00151-1","DOIUrl":"10.1016/S2589-7500(24)00151-1","url":null,"abstract":"<div><div>Cardiovascular diseases persist as the leading cause of death globally and their early detection and prediction remain a major challenge. Artificial intelligence (AI) tools can help meet this challenge as they have considerable potential for early diagnosis and prediction of occurrence of these diseases. Deep neural networks can improve the accuracy of medical image interpretation and their outputs can provide rich information that otherwise would not be detected by cardiologists. With recent advances in transformer models, multimodal AI, and large language models, the ability to integrate electronic health record data with images, genomics, biosensors, and other data has the potential to improve diagnosis and partition patients who are at high risk for primary preventive strategies. Although much emphasis has been placed on AI supporting clinicians, AI can also serve patients and provide immediate help with diagnosis, such as that of arrhythmia, and is being studied for automated self-imaging. Potential risks, such as loss of data privacy or potential diagnostic errors, should be addressed before use in clinical practice. This Series paper explores opportunities and limitations of AI models for cardiovascular medicine, and aims to identify specific barriers to and solutions in the application of AI models, facilitating their integration into health-care systems.</div></div>","PeriodicalId":48534,"journal":{"name":"Lancet Digital Health","volume":"6 10","pages":"Pages e767-e771"},"PeriodicalIF":23.8,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitigating the risk of artificial intelligence bias in cardiovascular care","authors":"Ariana Mihan MPH ,&nbsp;Ambarish Pandey MD ,&nbsp;Harriette GC Van Spall MD","doi":"10.1016/S2589-7500(24)00155-9","DOIUrl":"10.1016/S2589-7500(24)00155-9","url":null,"abstract":"<div><div>Digital health technologies can generate data that can be used to train artificial intelligence (AI) algorithms, which have been particularly transformative in cardiovascular health-care delivery. However, digital and health-care data repositories that are used to train AI algorithms can introduce bias when data are homogeneous and health-care processes are inequitable. AI bias can also be introduced during algorithm development, testing, implementation, and post-implementation processes. The consequences of AI algorithmic bias can be considerable, including missed diagnoses, misclassification of disease, incorrect risk prediction, and inappropriate treatment recommendations. This bias can disproportionately affect marginalised demographic groups. In this Series paper, we provide a brief overview of AI applications in cardiovascular health care, discuss stages of algorithm development and associated sources of bias, and provide examples of harm from biased algorithms. We propose strategies that can be applied during the training, testing, and implementation of AI algorithms to mitigate bias so that all those at risk for or living with cardiovascular disease might benefit equally from AI.</div></div>","PeriodicalId":48534,"journal":{"name":"Lancet Digital Health","volume":"6 10","pages":"Pages e749-e754"},"PeriodicalIF":23.8,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of risk prediction models to select lung cancer screening participants in Europe: a prospective cohort consortium analysis","authors":"Xiaoshuang Feng PhD ,&nbsp;Patrick Goodley MBBCh ,&nbsp;Karine Alcala MS ,&nbsp;Florence Guida PhD ,&nbsp;Prof Rudolf Kaaks PhD ,&nbsp;Prof Roel Vermeulen PhD ,&nbsp;George S Downward PhD ,&nbsp;Catalina Bonet MSc ,&nbsp;Sandra M Colorado-Yohar PhD ,&nbsp;Demetrius Albanes MD ,&nbsp;Stephanie J Weinstein PhD ,&nbsp;Prof Marcel Goldberg PhD ,&nbsp;Prof Marie Zins PhD ,&nbsp;Prof Caroline Relton PhD ,&nbsp;Prof Arnulf Langhammer PhD ,&nbsp;Anne Heidi Skogholt PhD ,&nbsp;Mattias Johansson PhD ,&nbsp;Hilary A Robbins PhD","doi":"10.1016/S2589-7500(24)00123-7","DOIUrl":"10.1016/S2589-7500(24)00123-7","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Lung cancer risk prediction models might efficiently identify individuals who should be offered lung cancer screening. However, their performance has not been comprehensively evaluated in Europe. We aimed to externally validate and evaluate the performance of several risk prediction models that predict lung cancer incidence or mortality in prospective European cohorts.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;We analysed 240 137 participants aged 45–80 years with a current or former smoking history from nine European countries in four prospective cohorts from the pooled database of the Lung Cancer Cohort Consortium: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (Finland), the Nord-Trøndelag Health Study (Norway), CONSTANCES (France), and the European Prospective Investigation into Cancer and Nutrition (Denmark, Germany, Italy, Spain, Sweden, the Netherlands, and Norway). We evaluated ten lung cancer risk models, which comprised the Bach, the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial 2012 model (PLCO&lt;sub&gt;m2012&lt;/sub&gt;), the Lung Cancer Risk Assessment Tool (LCRAT), the Lung Cancer Death Risk Assessment Tool (LCDRAT), the Nord-Trøndelag Health Study (HUNT), the Optimized Early Warning Model for Lung Cancer Risk (OWL), the University College London—Death (UCLD), the University College London—Incidence (UCLI), the Liverpool Lung Project version 2 (LLP version 2), and the Liverpool Lung Project version 3 (LLP version 3) models. We quantified model calibration as the ratio of expected to observed cases or deaths and discrimination using the area under the receiver operating characteristic curve (AUC). For each model, we also identified risk thresholds that would screen the same number of individuals as each of the US Preventive Services Task Force 2021 (USPSTF-2021), the US Preventive Services Task Force 2013 (USPSTF-2013), and the Nederlands–Leuvens Longkanker Screenings Onderzoek (NELSON) criteria.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;p&gt;Among the participants, 1734 lung cancer cases and 1072 lung cancer deaths occurred within five years of enrolment. Most models had reasonable calibration in most countries, although the LLP version 2 overpredicted risk by more than 50% in eight countries (expected to observed ≥1·50). The PLCO&lt;sub&gt;m2012&lt;/sub&gt;, LCDRAT, LCRAT, Bach, HUNT, OWL, UCLD, and UCLI models showed similar discrimination in most countries, with AUCs ranging from 0·68 (95% CI 0·59–0·77) to 0·83 (0·78–0·89), whereas the LLP version 2 and LLP version 3 showed lower discrimination, with AUCs ranging from 0·64 (95% CI 0·57–0·72) to 0·78 (0·74–0·83). When pooling data from all countries (but excluding the HUNT cohort), 33·9% (73 313 of 216 387) of individuals were eligible by USPSTF-2021 criteria, which included 74·8% (1185) of lung cancers and 76·3% (730) of lung cancer deaths occurring over 5 years. Fewer individuals were selected by USPSTF-2013 and NELSON criteria. After applying thresholds to select a ","PeriodicalId":48534,"journal":{"name":"Lancet Digital Health","volume":"6 9","pages":"Pages e614-e624"},"PeriodicalIF":23.8,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589750024001237/pdfft?md5=f39b6b82aa1c03f5fab734e0e84a6e1f&pid=1-s2.0-S2589750024001237-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142041014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A future role for health applications of large language models depends on regulators enforcing safety standards","authors":"Oscar Freyer ,&nbsp;Isabella Catharina Wiest Dr med ,&nbsp;Prof Jakob Nikolas Kather Dr med ,&nbsp;Stephen Gilbert PhD","doi":"10.1016/S2589-7500(24)00124-9","DOIUrl":"10.1016/S2589-7500(24)00124-9","url":null,"abstract":"<div><p>Among the rapid integration of artificial intelligence in clinical settings, large language models (LLMs), such as Generative Pre-trained Transformer-4, have emerged as multifaceted tools that have potential for health-care delivery, diagnosis, and patient care. However, deployment of LLMs raises substantial regulatory and safety concerns. Due to their high output variability, poor inherent explainability, and the risk of so-called AI hallucinations, LLM-based health-care applications that serve a medical purpose face regulatory challenges for approval as medical devices under US and EU laws, including the recently passed EU Artificial Intelligence Act. Despite unaddressed risks for patients, including misdiagnosis and unverified medical advice, such applications are available on the market. The regulatory ambiguity surrounding these tools creates an urgent need for frameworks that accommodate their unique capabilities and limitations. Alongside the development of these frameworks, existing regulations should be enforced. If regulators fear enforcing the regulations in a market dominated by supply or development by large technology companies, the consequences of layperson harm will force belated action, damaging the potentiality of LLM-based applications for layperson medical advice.</p></div>","PeriodicalId":48534,"journal":{"name":"Lancet Digital Health","volume":"6 9","pages":"Pages e662-e672"},"PeriodicalIF":23.8,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589750024001249/pdfft?md5=2df13b013a0e89af3fe332b6bcb83ed0&pid=1-s2.0-S2589750024001249-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142041038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balancing AI innovation with patient safety","authors":"The Lancet Digital Health","doi":"10.1016/S2589-7500(24)00175-4","DOIUrl":"10.1016/S2589-7500(24)00175-4","url":null,"abstract":"","PeriodicalId":48534,"journal":{"name":"Lancet Digital Health","volume":"6 9","pages":"Page e601"},"PeriodicalIF":23.8,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589750024001754/pdfft?md5=0a8eaf69e78527e6cec35e921968cd32&pid=1-s2.0-S2589750024001754-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142041039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Digit Health 2024; 6: e605–13","authors":"","doi":"10.1016/S2589-7500(24)00176-6","DOIUrl":"10.1016/S2589-7500(24)00176-6","url":null,"abstract":"","PeriodicalId":48534,"journal":{"name":"Lancet Digital Health","volume":"6 9","pages":"Page e604"},"PeriodicalIF":23.8,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589750024001766/pdfft?md5=11bd2424e9355f76c22900c4a010ada2&pid=1-s2.0-S2589750024001766-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reporting standards to support cost-effectiveness evaluations of AI-driven health care","authors":"Jamie Elvidge ,&nbsp;Dalia Dawoud","doi":"10.1016/S2589-7500(24)00171-7","DOIUrl":"10.1016/S2589-7500(24)00171-7","url":null,"abstract":"","PeriodicalId":48534,"journal":{"name":"Lancet Digital Health","volume":"6 9","pages":"Pages e602-e603"},"PeriodicalIF":23.8,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589750024001717/pdfft?md5=38bf3554f6e2ebc110a0128fd57b4837&pid=1-s2.0-S2589750024001717-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142041040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiological presentation and risk factors of long COVID in the UK using smartphones and wearable devices: a longitudinal, citizen science, case–control study","authors":"Callum Stewart PhD ,&nbsp;Yatharth Ranjan MSc ,&nbsp;Pauline Conde MSc ,&nbsp;Shaoxiong Sun PhD ,&nbsp;Yuezhou Zhang PhD ,&nbsp;Zulqarnain Rashid PhD ,&nbsp;Heet Sankesara BSc ,&nbsp;Nicholas Cummins PhD ,&nbsp;Petroula Laiou PhD ,&nbsp;Xi Bai PhD ,&nbsp;Prof Richard J B Dobson PhD ,&nbsp;Amos A Folarin PhD","doi":"10.1016/S2589-7500(24)00140-7","DOIUrl":"10.1016/S2589-7500(24)00140-7","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;The emergence of long COVID as a COVID-19 sequela was largely syndromic in characterisation. Digital health technologies such as wearable devices open the possibility to study this condition with passive, objective data in addition to self-reported symptoms. We aimed to quantify the prevalence and severity of symptoms across collected mobile health metrics over 12 weeks following COVID-19 diagnosis and to identify risk factors for the development of post-COVID-19 condition (also known as long COVID).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;The Covid Collab study was a longitudinal, self-enrolled, community, case–control study. We recruited participants from the UK through a smartphone app, media publications, and promotion within the Fitbit app between Aug 28, 2020, and May 31, 2021. Adults (aged ≥18 years) who reported a COVID-19 diagnosis with a positive antigen or PCR test before Feb 1, 2022, were eligible for inclusion. We compared a cohort of 1200 patients who tested positive for COVID-19 with a cohort of 3600 sex-matched and age-matched controls without a COVID-19 diagnosis. Participants could provide information on COVID-19 symptoms and mental health through self-reported questionnaires (active data) and commercial wearable fitness devices (passive data). Data were compared between cohorts at three periods following diagnosis: acute COVID-19 (0–4 weeks), ongoing COVID-19 (4–12 weeks), and post-COVID-19 (12–16 weeks). We assessed sociodemographic and mobile health risk factors for the development of long COVID (defined as either a persistent change in a physiological signal or self-reported symptoms for ≥12 weeks after COVID-19 diagnosis).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;p&gt;By Aug 1, 2022, 17 667 participants had enrolled into the study, of whom 1200 (6·8%) cases and 3600 (20·4%) controls were included in the analyses. Compared with baseline (65 beats per min), resting heart rate increased significantly during the acute (0·47 beats per min; odds ratio [OR] 1·06 [95% CI 1·03–1·09]; p&lt;0·0001), ongoing (0·99 beats per min; 1·11 [1·08–1·14]; p&lt;0·0001), and post-COVID-19 (0·52 beats per min; 1·04 [1·02–1·07]; p=0·0017) phases. An increased level of historical activity in the period from 24 months to 6 months preceding COVID-19 diagnosis was protective against long COVID (coefficient –0·017 [95% CI –0·030 to –0·003]; p=0·015). Depressive symptoms were persistently elevated following COVID-19 (OR 1·03 [95% CI 1·01–1·06]; p=0·0033) and were a potential risk factor for developing long COVID (1·14 [1·07–1·22]; p&lt;0·0001).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;p&gt;Mobile health technologies and commercial wearable devices might prove to be a useful resource for tracking recovery from COVID-19 and the prevalence of its long-term sequelae, as well as representing an abundant source of historical data. Mental wellbeing can be impacted negatively for an extended period following COVID-19.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;p&gt;National ","PeriodicalId":48534,"journal":{"name":"Lancet Digital Health","volume":"6 9","pages":"Pages e640-e650"},"PeriodicalIF":23.8,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589750024001407/pdfft?md5=41fde3576005e91fa40bb70d2e644041&pid=1-s2.0-S2589750024001407-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital solutions in paediatric sepsis: current state, challenges, and opportunities to improve care around the world","authors":"L Nelson Sanchez-Pinto MD ,&nbsp;María del Pilar Arias López MD ,&nbsp;Halden Scott MD ,&nbsp;Kristen Gibbons PhD ,&nbsp;Michael Moor PhD ,&nbsp;Prof R Scott Watson MD ,&nbsp;Matthew O Wiens PhD ,&nbsp;Prof Luregn J Schlapbach MD ,&nbsp;Tellen D Bennett MD","doi":"10.1016/S2589-7500(24)00141-9","DOIUrl":"10.1016/S2589-7500(24)00141-9","url":null,"abstract":"<div><p>The digitisation of health care is offering the promise of transforming the management of paediatric sepsis, which is a major source of morbidity and mortality in children worldwide. Digital technology is already making an impact in paediatric sepsis, but is almost exclusively benefiting patients in high-resource health-care settings. However, digital tools can be highly scalable and cost-effective, and—with the right planning—have the potential to reduce global health disparities. Novel digital solutions, from wearable devices and mobile apps, to electronic health record-embedded decision support tools, have an unprecedented opportunity to transform paediatric sepsis research and care. In this Series paper, we describe the current state of digital solutions in paediatric sepsis around the world, the advances in digital technology that are enabling the development of novel applications, and the potential effect of advances in artificial intelligence in paediatric sepsis research and clinical care.</p></div>","PeriodicalId":48534,"journal":{"name":"Lancet Digital Health","volume":"6 9","pages":"Pages e651-e661"},"PeriodicalIF":23.8,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589750024001419/pdfft?md5=31f8722a8d750546a71029215e4dfdf0&pid=1-s2.0-S2589750024001419-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}